DossierENTITY

cross-border biotech deals

Coverage of cross-border biotech deals in the Nexus archive.

Earliest in view: Jun 21 · 01:30 UTCMost recent: Jun 21 · 01:30 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJun 21 · 01:30 UTCSCMP WORLD
Cross-border biotech deals grow more complex as US targets China investment links
Cross-border biotech deals between China and the United States are becoming more complex as the U.S. targets investment links, leading to potential slowdowns, according to analysts. Diederik Stadig of ING Research noted increased geopolitical scrutiny may result in fewer deals.